Spanish National Research Council (CSIC)

A lightweight robotic device aids neuromuscular recovery in children with spinal muscular atrophy, helping them to stand unaided, according to a study published in Nature. The research involved six participants aged between six and 10 and shows that the device achieved significant improvements in lower limb motor function after six weeks of assisted training. The study highlights that the improvement persists after training is discontinued and conventional physiotherapy routines are resumed, demonstrating the potential for lasting recovery.  

The US company Colossal Biosciences claims to have successfully incubated a bird in an artificial egg system until it hatched. In a press release, the company states that this technology allows a bird embryo to develop fully outside the shell of a biological egg, and could be used to bring back extinct bird species such as the giant moa from New Zealand’s South Island.

Decades ago, concerns began to be raised about the decline in honeybee populations. Although their situation has improved, the same cannot be said for other pollinating insects. Together, they enable the reproduction of nearly 90% of flowering plants and directly contribute to three out of every four crops that feed the world. We examine the causes of this decline, their current situation, and the measures being taken to protect them.

A team from the United States analyzed 611 samples from 341 model mouse strains stored at the Mutant Mouse Resource and Research Centers (MMRRC), a research resource network supported by the National Institutes of Health (NIH). By comparing the identity of each strain with its actual genetic profile, they found that approximately half of the samples showed discrepancies. Although the expected engineered mutation was generally present and many inconsistencies were relatively minor, some had the potential to compromise the validity and reproducibility of the experiments by introducing hidden genetic variables that could alter biological outcomes. The findings are published in Science.

Craig Venter, the American biologist and entrepreneur who founded Celera Genomics to launch his own Human Genome Project in 1999 outside the public consortium, died Wednesday in San Diego at the age of 79, according to a statement from the J. Craig Venter Institute, which he led. Among other achievements, Venter completed the first full sequencing of a living organism’s genetic material and announced that he had succeeded in creating synthetic life.

Rapid warming in Europe is reducing snow and ice cover, while very high air temperatures, drought, heatwaves, and record ocean temperatures are affecting regions from the Arctic to the Mediterranean. These are the main findings of the State of the Climate in Europe (ESOTC) 2025 report, prepared by the European Centre for Medium-Range Weather Forecasts (ECMWF), which operates the Copernicus Climate Change Service, and by the World Meteorological Organization (WMO). The data show that 95% of the continent recorded above-average annual temperatures last year, and river flows were below average for 11 months.

A study published in Science analyzed more than 100,000 human neocortical cells from weeks 13 to 23 of gestation, when cortical neurons are generated. The samples came from 26 donors, some with and others without Down syndrome. Using single-cell genomics, they observed how trisomy 21 disrupts the developmental sequence of various types of neurons, which could explain subsequent differences in cognition. A second study in the same journal, which examines the postnatal brains of children with Down syndrome, finds that many of these changes persist into childhood. The authors note that their study will not have short-term clinical applications, but they hope it can be used to develop specific drugs or create gene therapies. 

One of the best-known genetic risk factors for developing Parkinson’s disease is carrying variants of the GBA1 gene. A new study published in the journal Nature Medicine compared the microbiomes of 43 carriers of this gene who had not developed the disease with those of 271 Parkinson’s patients and 150 healthy individuals. The results showed, in addition to alterations in the microbiome in the patient group, that 25% of the microbiome of carriers of this gene exhibited alterations, representing an intermediate profile between the other two groups. The results were validated using independent cohorts from the United Kingdom, South Korea, and Turkey. According to the authors, “alterations in the gut microbiome can identify individuals with both genetic and non-genetic risk in the general population who may be progressing toward Parkinson’s disease.”
 

A US team analyzed the genetic activity of individual brain cells from 15 men and 15 women and found 133 genes that showed consistent differences. Although biological sex explained only a small part of the differences they found when comparing all the brains, variants in many of these genes have been associated with neuropsychiatric and neurodegenerative disorders—such as ADHD, schizophrenia, depression, and Alzheimer's—suggesting that sex differences could play a role in the distinct risk men and women have of developing certain diseases. The authors, however, acknowledge that the sex-related differences in their study could stem from differences in socialization and experience. The results are published in Science.  

A review of studies conducted by the Cochrane Collaboration analyzed data from 17 clinical trials involving more than 20,000 participants who had been treated with amyloid-targeting drugs—such as lecanemab or donanemab—at a relatively early stage of Alzheimer’s disease. Results at 18 months of treatment show that “the absolute effects on cognitive decline and the severity of dementia were nonexistent or negligible, falling well below the thresholds established for a clinically meaningful difference,” according to a press release. Furthermore, the review concludes that these drugs likely cause more brain inflammation and microbleeds than the placebo.